24/7 Market News Snapshot 20 May, 2025 – Neuraxis, Inc. (NYSE:NRXS)

May 20, 2025

DENVER, Colo., 20 May, 2025 (www.247marketnews.com) – (NYSE:NRXS) are discussed in this article.
Neuraxis, Inc. (NRXS) is experiencing significant momentum in the market, highlighted by a pre-market trading surge to $6.317, a striking increase of 178.28% from its previous close at $2.270. This impressive rise in share value is underpinned by a substantial trading volume of 10.39 million shares, showcasing robust investor confidence in the company’s future prospects within the biotech sector. Analysts suggest that this bullish trend presents a compelling opportunity for investors, positioning Neuraxis as a dynamic contender in the industry.

In a landmark achievement, Neuraxis has also announced that it has obtained FDA 510(k) clearance for its innovative IB-Stim™ device, designed to treat Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia and related symptoms in patients aged 8 to 21 years. This notable clearance represents a historic advancement as it marks the first FDA-approved treatment targeting functional dyspepsia, thereby broadening the scope of IB-Stim’s application in the pediatric healthcare space.

The FDA approval is expected to nearly double Neuraxis’s total addressable market, solidifying its position as a leader in non-invasive neuromodulation therapies for children. The IB-Stim device administers gentle electrical impulses to cranial nerve bundles in the ear, offering a groundbreaking alternative in an area previously lacking FDA-approved pharmacological treatments for abdominal pain-related disorders in pediatric patients.

Brian Carrico, President and CEO of Neuraxis, emphasized the significance of this approval, stating, “This expansion broadens our clinical impact while offering a seamless go-to-market strategy backed by existing reimbursement and provider networks.” Meanwhile, Chief Medical Officer Dr. Adrian Miranda expressed enthusiasm about the potential to alleviate the struggles faced by many families dealing with functional dyspepsia, paving the way for further innovations as the company advances its ongoing clinical trials.

Related news for (NRXS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.